FDA has approved new oral testosterone capsule (Jatenzo) for treatment of men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. Jatenzo should not be used to treat men with "age-related hypogonadism," in which testosterone levels decline due to aging, even if these men have symptoms that appear to be related to low testosterone. Jatenzo's benefits do not outweigh its risks for that use including its effects on raising blood pressure that increase the risks of heart attack, stroke and cardiovascular death in this population.
FDA Commissioner Scott Gottlieb, M.D. has announced enforcement discretion to accommodate unique circumstances faced by producers of hops, wine grapes, pulse crops and almonds. The Food Safety Modernization Act empowered the FDA to enact a more modern, preventive and risk-based approach to food safety with a focus on setting common-sense safety standards for food producers to protect public health, so after they received feedback on the application of this rule from stakeholders of certain commodities, including hops, wine grapes, pulse crops and almonds, the FDA does not expect producers of these commodities to comply with the Produce Safety Rule.
Warning Letters (the following are representative samples of warning letters issued this month)
Tec Laboratories, Inc. Albany, OR 97321
1. Failure to conduct appropriate laboratory testing, as necessary, of each batch of topical OTC and homeopathic drug product required to be free of objectionable microorganisms.
2. Failure to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.
3. Your firm is marketing an unapproved new drug advertised as "Calagel".
B. Jain Pharmaceuticals Pvt. Ltd., Bhiwadi-301707 Rajasthan, India
1. Your firm failed to maintain the buildings used in the manufacture, processing, packing, or holding of a drug product in a clean and sanitary condition and to keep them free of infestation by rodents, birds, insects, and other vermin.
2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.
3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products.
4. Your firm is marketing misbranded homeopathic drugs.
King Bio, Inc., Asheville, NC, Inc. 28806
1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products.
2. Your firm failed to establish adequate written procedures for production (e.g. process validation) and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.
3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance.
Inopak Ltd., Ringwood, NJ 07456
1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.
2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing.
3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit.
4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess.
Nutra Pharma Corp. Coral Springs, FL 33071
You are illegally marketing unapproved products labeled as homeopathic with claims about their ability to treat addiction and chronic pain, including pain associated with cancer, diabetes, shingles, fibromyalgia and other serious conditions.
|